Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Humanwell Healthcare (group) Co., Ltd.

Medshine Discovery Inc.

Humanwell Healthcare Co., Ltd.

Hailiang Chen

Yong Xu

Lu Huang

Xuehai Wang

Ronghua Tu

Wenjie Sun

Shuhui Chen

Yong Wang

Lie Li

Cailin Wang

Jie Shen

Charles Z Ding

Zheng Wang

Cong Wang

Hui Liu

Weidong Li

Yang Yue

Yang YuE

Biao Deng

Jimeng Wang

Guoping Hu

Chengde Wu

Yi Zhang

Zhaozhong Ding

Chunli Shen

Jian Li

Zhibo Zhang

Wen Zhou

Jing Yang

Qiang Xiao

Zhongwen Yang

Nengyang Shi

Li'e Li

Hua Tian

Yanping Yu

Jing Tang

Diliang Guo

Quan Liu

Jing Yu

Zhenyu He

Xuwen Zhang

Gang Li

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound has the structure of Compound 2. 

Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV). 

BTK inhibitor

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1,5-alpha]benzimidazole compound and a preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound is represented by formula I: 

Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Disclosed is a series of analogs of 4H-pyrazolo[1,5-&#x3b1;]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors

Growing community of inventors

Hubei, China

Hailiang Chen